In situ delivery and production system of trastuzumab scFv with Bifidobacterium

In Situ Delivery and Production System (iDPS) of Anti-Cancer Molecules with Gene-Engineered Bifidobacterium

“…We succeeded in making not only an expression, but also a secretion, system for a biologically active scFv derived from the anti-HER2 trastuzumab with Bifidobacterium ( Figure 5 ) [ 58 ]. Production of the scFv to human HER2 was confirmed by Western blot analysis.…”

“…Production of the scFv to human HER2 was confirmed by Western blot analysis. We also verified biochemical activity by FACS and immunological staining [ 58 ]. The genetically modified bacteria were injected into nude mice bearing the human HER2-positive breast cancer, NCI-N87.…”

“…The genetically modified bacteria were injected into nude mice bearing the human HER2-positive breast cancer, NCI-N87. We witnessed selective localization of the bacteria inside the tumor, secretion of anti-HER2 single-chain antibodies, and ultimately a suppressive effect on tumor growth ( Figure 5 ) [ 58 ]. This success in creating Bifidobacterium to express and secrete the biologically active trastuzumab scFv prompted us to establish i DPS with Bifidobacterium for ICPIs.…”

“…*: p < 0.05 versus non-treated group, #: p < 0.05 versus mock-treated group. This figure was adopted from a previous study [ 58 ].…”

Towards the use of localised delivery strategies to counteract cancer therapy–induced cardiotoxicities

“…Additionally, the bacteria were locally injected into xenografted human HER2-positive tumours and found to inhibit tumour growth representing a promising strategy for localised sustained release of such therapeutics (73). Another promising strategy is the localised delivery of an alpha particle emitting radionucleotide 25 Ac-T linked to trastuzumab to target HER2 positive tumours via intraductal injection.…”